REGADENOSON
Total Payments
$917,193
Transactions
51
Doctors
7
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $902,643 | 50 | 7 |
| 2017 | $14,550 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $878,378 | 38 | 95.8% |
| Consulting Fee | $38,356 | 4 | 4.2% |
| Education | $458.80 | 9 | 0.1% |
Payments by Type
Research
$878,378
38 transactions
General
$38,814
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HF with Preserved EF | Astellas Pharma Global Development | $163,488 | 0 |
| The Prognostic Value of Stress SPECT Myocardial Perfusion Imaging versus Stress Echocardiography | Astellas Pharma Global Development | $123,750 | 0 |
| Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography with a novel 3rd generation dual-source CT system | Astellas Pharma Global Development | $92,021 | 0 |
| Heart rate response to regadenoson and sudden cardiac death | Astellas Pharma Global Development | $63,087 | 0 |
| Functional Assessment of Coronary Artery Disease by Quantitative CTA Flow Encoding | Astellas Pharma Global Development | $61,389 | 0 |
| Characteristics and outcomes of patients selected to undergo pharmacologic myocardial perfusion stress testing using regadenoson-facilitated single-photon emission computerized tomography SPECT a retrospective study using a tertiary care database | Astellas Pharma Global Development | $61,203 | 0 |
| REDUCING RADIOISOTOPE DOSE IN REGADENOSON SPECT MYOCARDIAL PERFUSION IMAGING COMPARISON OF HALF-DOSE SCANS USING A NOVEL SOLID-STATE-DETECTOR DEDICATED CARDIAC CAMERA TO FULL DOSE SCANS ACQUIRED ON STANDARD EQUIPMENT | Astellas Pharma Global Development | $60,438 | 0 |
| Impact of Appropriate Use on the Cost-Effectiveness of SPECT Myocardial Perfusion Imaging in Patients with Known or Suspected Stable Ischemic Heart Disease | Astellas Pharma Global Development | $55,885 | 0 |
| Assessment and prognostic significance of global myocardial perfusion reserve MPR using coronary sinus flow measurements during Regadenoson stress CMR | Astellas Pharma Global Development | $41,800 | 0 |
| Coronary flow reserve PET vs Invasive Angiography. A retrospective analysis | Astellas Pharma Global Development | $36,342 | 0 |
| Diagnostic and prognostic value of the stress induced right ventricular uptake on Lexiscan stress MPI in patients with known or suspected coronary artery disease | Astellas Pharma Global Development | $33,969 | 0 |
| Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease | Astellas Pharma Global Development | $31,875 | 0 |
| The Simultaneous Assessment of Invasive Fractional Flow Reserve and Myocardial Perfusion by SPECT Using Regadenoson in the Catheterization Laboratory. | Astellas Pharma Global Development | $28,000 | 0 |
| Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction | Astellas Pharma Global Development | $12,616 | 0 |
| Assessment of Myocardial Flow Reserve and Effects of Exercise Traiing in Patients with Angina and Negative Coronary Angiograms | Astellas Pharma Global Development | $12,083 | 0 |
| Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HF with Preserved EF | Astellas US Technologies | $237.03 | 0 |
| None | Astellas Pharma Global Development | $197.50 | 2 |
Top Doctors Receiving Payments for REGADENOSON
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $878,181 | 36 |
| , MD | Nuclear Medicine | Cleveland, OH | $31,756 | 3 |
| , M.D | Internal Medicine | Detroit, MI | $6,699 | 2 |
| , MD.,F.A.C.C.,F.A.C.P | Cardiovascular Disease | Tamarac, FL | $191.30 | 4 |
| , MD | Cardiovascular Disease | Fort Lauderdale, FL | $107.00 | 2 |
| , M.D | Cardiovascular Disease | Weston, FL | $107.00 | 2 |
| , D.O | Internal Medicine | Detroit, MI | $98.75 | 1 |
| Warren Moore | — | Houston, TX | $53.50 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $916,956
- Astellas US Technologies $237.03
Product Information
- Type Drug
- Total Payments $917,193
- Total Doctors 7
- Transactions 51
About REGADENOSON
REGADENOSON is a drug associated with $917,193 in payments to 7 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2018. In 2018, $902,643 was paid across 50 transactions to 7 doctors.
The most common payment nature for REGADENOSON is "Unspecified" ($878,378, 95.8% of total).
REGADENOSON is associated with 17 research studies, including "Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HF with Preserved EF" ($163,488).